Wilson Therapeutics Stock Performance and Acquisition

Wilson Therapeutics has seen a significant stock performance in recent years. The company's stock price has increased by over 50% in the past year alone.

In 2019, Wilson Therapeutics was acquired by Alexion Pharmaceuticals for $250 million. This acquisition marked a major milestone for the company.

The acquisition was a strategic move for Alexion, allowing them to expand their portfolio and gain access to Wilson Therapeutics' expertise in developing treatments for rare diseases.

Intriguing read: Beijing Stock Exchange

Wilson Therapeutics was delisted from Nasdaq Stockholm, with the last day of trading being 15 June 2018.

The company's stock ticker was WTX, and it was listed in the Mid Cap segment on Nasdaq Stockholm.

Wilson Therapeutics' lead product, WTX101, was in Phase 3 development as a novel treatment for Wilson Disease.

The public offer by Alexion Pharmaceuticals, Inc. for the shares in Wilson Therapeutics was declared unconditional on 25 May 2018.

Alexion owned more than 90 per cent of the shares in Wilson Therapeutics and intended to request compulsory acquisition for the remaining shares.

The acceptance period for Alexion's offer was extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders to accept the offer.

Wilson Therapeutics itself applied for delisting from Nasdaq Stockholm.

Alibaba Group Year-End Report 2017 is not relevant to Wilson Therapeutics, but let's talk about Wilson Therapeutics' financial performance.

Wilson Therapeutics' net sales were SEK 0.0 M for the period January 1 - March 31, 2018, and also for the period July 1 – September 30, 2017.

The company's loss for the period January 1 - March 31, 2018, was SEK 68.9 M, which is an increase from the loss of SEK 29.4 M for the period July 1 – September 30, 2017.

At March 31, 2018, Wilson Therapeutics had SEK 426.7 M in cash and cash equivalents, which is an increase from SEK 277.1 M at September 30, 2017.

Wilson Therapeutics announced a public cash offer to acquire the company after the end of the reporting period for January 1 - March 31, 2018.

For another approach, see: July Systems

Wilson Therapeutics regularly hosts conference calls to provide business updates. These events are usually held in the morning and afternoon of the same day as the publication of their reports.

The company publishes its year-end report in February and its interim report in November. The year-end report for 2017 was published on February 21, 2018, at 07:00 CET.

To participate in the conference call, you can join the live webcast or listen to a recorded on-demand version, both of which include the presentation material. The webcasts are available at tv.streamfabriken.com.

The annual general meeting is a crucial event for shareholders to gather and discuss the company's progress. It's usually held once a year, as seen in the case of Wilson Therapeutics AB, which had its annual general meeting on Monday, 18 June 2018.

Shareholders must be recorded in the share register maintained by Euroclear Sweden AB by a specific date, in this case, Tuesday, 12 June 2018. This ensures that they're eligible to participate in the meeting.

To attend the meeting, shareholders must notify the company in advance, by post or phone. For Wilson Therapeutics, the notification deadline was also Tuesday, 12 June 2018.

Wilson Therapeutics hosts Capital Markets Day today at 13:30 CET/08:30 EDT.

The event will take place in Stockholm and will include an in-depth discussion on Wilson Disease and the company's candidate drug, WTX101, currently in Phase 3 development for Wilson Disease.

During the event, pre-clinical data, data from the company's Phase 2 study and the design of the Phase 3 study will be described further.

The company's market analysis and commercial planning will also be presented.

Members from the senior management team will be joined by Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan.

Wilson Therapeutics received a bid from Alexion, a US pharmaceutical company, offering 232 kronor per share in cash, which translates to a total bid value of approximately 6.6 billion kronor.

The bid was made for the Swedish research company Wilson Therapeutics.

This significant bid highlights the interest of major pharmaceutical companies in innovative treatments, such as Wilson Therapeutics' investigational oral first-in-class copper-protein binding agent for Wilson Disease.

The bid is a testament to the potential of Wilson Therapeutics' research and development efforts.

Professor Michael Schilsky, Director of the Center for Excellence for Wilson Disease at Yale University Medical Center, is presenting preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 at The Liver Meeting.

Carnegie has raised the price target for Wilson Therapeutics to 158 kronor from 120 kronor.

This shows a significant increase in their confidence in the company's potential.

Carnegie has reaffirmed their recommendation for Wilson Therapeutics.

Their expertise in the field likely influenced this decision.

The new price target is a notable change from the previous one, indicating a shift in Carnegie's stance.

Wilson Therapeutics is committed to keeping its investors informed through regular updates and events. The company has a strong track record of transparency, as seen in its announcement of the agenda for its Capital Markets Day in 2018.

The Capital Markets Day was held in Stockholm on March 21, 2018, and featured a discussion on Wilson Disease and WTX101, a first-in-class copper-protein-binding agent. Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan, joined the senior management team to provide expert insights.

Investors can expect to stay up-to-date on the company's progress through events like the Capital Markets Day, which showcase the latest developments in Wilson Disease treatment.

Wilson Therapeutics is hosting a Capital Markets Day on March 21, 2018, in Stockholm.

The event will take place at 13:30 CET/08:30 EDT, and it's open to investors, analysts, and media.

Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan, will be joining the senior management team.

The program will include an in-depth discussion on Wilson Disease and the company's candidate drug, WTX101, which is currently in Phase 3 development.

Pre-clinical data, data from the company's Phase 2 study, and the design of the Phase 3 study will be presented.

The company's market analysis and commercial planning will also be discussed.

The agenda for the Capital Markets Day has been announced, and it includes a welcome and introduction to the event.

Dr. Askari will be part of the discussion on Wilson Disease and WTX101, a first-in-class copper-protein-binding agent with a unique mechanism of action.

Wilson Therapeutics has a total of 28,292,272 shares and votes, following a recent directed share issue that increased the number by 2,572,024.

The company's CFO, Anders Martin-Löf, is the contact person for further information and can be reached at +46 8 796 00 00 or [email protected].

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, with the company registration number 556893-0357.

Wilson Therapeutics has appointed a Nomination Committee, which is a common practice in corporate governance. The committee consists of four members, including the Chairman of the Board.

Andrew Kay, the Chairman of the Board, is a member of the committee. He brings a wealth of experience to the table.

Staffan Lindstrand, representing HealthCap, is also a member of the committee. HealthCap is one of the largest shareholders of Wilson Therapeutics.

Sarah Shackelton, representing Abingworth, is another member of the committee. Abingworth is another large shareholder of the company.

Thomas Casdagli, representing MVM, rounds out the committee. MVM is the third largest shareholder of Wilson Therapeutics.

Carnegie höjer riktkursen för Wilson Therapeutics till 158 kronor från 120 kronor.

Carnegie och Kempen är två kända analyshus som har höjt sin riktkurs för Wilson Therapeutics.

Kempen har höjt riktkursen till 180 kronor, från tidigare 110 kronor, och har en köprekommendation.

Rekommendationen från Carnegie är dock att behålla, med en ny riktkurs på 158 kronor.

Wilson Therapeutics is a biopharmaceutical company that focuses on developing treatments for rare genetic disorders.

The company's lead product, KCD-035, is being developed to treat Wilson's disease, a rare genetic disorder that affects the body's ability to remove excess copper.

KCD-035 has shown promising results in clinical trials, with a significant reduction in liver copper levels in patients.

Wilson Therapeutics has also been working on a second product candidate, KCD-002, which is being developed to treat another rare genetic disorder, Menkes disease.

The company has a strong focus on research and development, with a team of experienced scientists and researchers working to identify and develop new treatments for rare genetic disorders.

Wilson Therapeutics has received funding and support from various organizations, including the Swedish Research Council and the European Union's Horizon 2020 program.

Alexion Pharmaceuticals, Inc. has agreed to acquire Wilson Therapeutics for a total of $855 million. The acquisition is expected to close in the second quarter of 2018.

Alexion has offered SEK 232 in cash for each outstanding share of Wilson Therapeutics. This amount translates into a total transaction value of $855 million.

The acquisition will add a late-stage candidate, WTX101, to Alexion's pipeline. WTX101 is a first-in-class oral copper-binding agent with a unique mechanism of action.

WTX101 is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. The candidate has also obtained Fast Track designation in the United States and enjoys Orphan Drug Designation for the treatment of Wilson disease in the United States and EU.

Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris.

A fresh viewpoint: United Therapeutics

Wilson Therapeutics' stock performance has been quite volatile over the years. The company's stock price has fluctuated significantly due to various market and clinical trial-related factors.

In 2014, Wilson Therapeutics' stock price was around 2.5 SEK per share. This was before the company began its clinical trials for its lead product, deflazacort.

The company's stock price surged in 2016 after it announced positive top-line results from a Phase 2 clinical trial for deflazacort. This led to a significant increase in the stock price, reaching around 25 SEK per share.

However, the stock price declined in 2017 due to concerns about the regulatory pathway for deflazacort in the US.

For another approach, see: Juno Therapeutics Stock Symbol